ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Clark, Hutchinson Gain New Honors; Nominations Open For Bristol-Myers Award; NIH Appointments

July 1, 1983

In Brief: Allegra To Head NCI/Navy Branch; Sausville Promoted; Gladstein To Leave NCI For Dallas

October 25, 1991

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

Tobacco Council Awards 34 New Grants

April 16, 1982

Radiotherapy Plus Cetuximab May Control Head/Neck Cancer

November 26, 2010

Millers Win Bristol-Myers $25,000 Award

May 19, 1978